Company news

Alvotech news in 2026

Alvotech's news releases, calls and decks from 2026, newest first.

View company

Alvotech to Present at Upcoming Investor Conferences in November

November 2, 2026

Alvotech to Present at Upcoming Investor Conferences in November

November 2, 2026

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

October 28, 2026

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

October 20, 2026

Alvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per Batch

October 20, 2026

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

October 14, 2026

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

October 14, 2026

Alvotech: Half yearly financial audit reports reviews 2026 10 07 13h09m51 (1)

October 12, 2026

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

October 6, 2026

Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply

October 6, 2026

FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®

October 5, 2026

Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations

August 31, 2026

Alvotech to present at upcoming investor conferences in September

August 27, 2026

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

August 21, 2026

Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update

August 19, 2026

Alvotech announces successful closure of FDA inspection of manufacturing facility

July 29, 2026

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

June 18, 2026

Alvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private Placement

June 15, 2026

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

June 15, 2026

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

June 8, 2026

Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®

June 4, 2026

Alvotech to present at upcoming investor conferences in June

June 2, 2026

Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland

May 31, 2026

Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility

May 11, 2026

Alvotech Q1 2026 Financial Results

May 6, 2026

Alvotech Announces a Change in its Executive Team

April 30, 2026

Alvotech to Report Financial Results for the First Quarter of 2026

April 24, 2026

Alvotech Publishes 2025 Annual Report

March 29, 2026

Alvotech Files Annual Report with the SEC

March 29, 2026

Alvotech files Annual Report with the SEC

March 29, 2026

Alvotech Q4 2025 and Full Year 2025 Financial Results

March 17, 2026

Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results

March 3, 2026

Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®

February 4, 2026

Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates

February 1, 2026

Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg

January 28, 2026

Correction: Transactions of Managers and Closely Associated Persons

January 6, 2026

Alvotech announces planned CEO succession and leadership transition

January 6, 2026

Transactions of Managers and Closely Associated Persons

January 5, 2026

Calls in 2026

Decks in 2026